reports
- Carole Braudeau
- Jerôme Bodin
BN DANONE SA
MC LVMH MOET HENNESSY LOUIS VUITTON SE
RI PERNOD RICARD SA
LISN CHOCOLADEFABRIKEN LINDT & SPRUENGLI AG
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
POM PLASTIC OMNIUM SE
MERY MERCIALYS SA
BEI BEIERSDORF AG
EL ESSILORLUXOTTICA SA
NESN NESTLE S.A.
VIV VIVENDI SE
BRBY BURBERRY GROUP PLC
OR L'OREAL SA
KER KERING SA
SDF K+S AG
HEN3 HENKEL AG & CO. KGAA PREF
01913 PRADA S.P.A.
MONC MONCLER SPA
ENG ENAGAS SA
CPS CYFROWY POLSAT SA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
LFDE LA FRANCAISE DE L'ENERGIE SA
CPR DAVIDE CAMPARI-MILANO N.V.
ALLFG ALLFUNDS (UK) LTD
ZGN ERMENEGILDO ZEGNA NV
CABKA CABKA N.V.
GALD GALDERMA GROUP AG
PUIG PUIG BRANDS
ATO ATOS SE
ULVR UNILEVER PLC
- Jerôme Bodin
BN DANONE SA
MC LVMH MOET HENNESSY LOUIS VUITTON SE
RI PERNOD RICARD SA
LISN CHOCOLADEFABRIKEN LINDT & SPRUENGLI AG
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
POM PLASTIC OMNIUM SE
MERY MERCIALYS SA
BEI BEIERSDORF AG
EL ESSILORLUXOTTICA SA
NESN NESTLE S.A.
VIV VIVENDI SE
BRBY BURBERRY GROUP PLC
OR L'OREAL SA
KER KERING SA
SDF K+S AG
HEN3 HENKEL AG & CO. KGAA PREF
01913 PRADA S.P.A.
MONC MONCLER SPA
ENG ENAGAS SA
CPS CYFROWY POLSAT SA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
LFDE LA FRANCAISE DE L'ENERGIE SA
CPR DAVIDE CAMPARI-MILANO N.V.
ALLFG ALLFUNDS (UK) LTD
ZGN ERMENEGILDO ZEGNA NV
CABKA CABKA N.V.
GALD GALDERMA GROUP AG
PUIG PUIG BRANDS
ATO ATOS SE
ULVR UNILEVER PLC
- Carole Braudeau
- Anthony Dick
- Michael Foundoukidis
- Anthony Dick
- Michael Foundoukidis
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 20...
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026Availability of the Preparatory Documents PARIS, France, April 20, 2026, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, informs its shareholders that its ordina...
- Tobias Fahrenholz
- Tobias Fahrenholz
- Martial Descoutures
Abivax : Why does Crohn's disease represent a major opportunity for Ab...
At this stage, speculative interest in Abivax still appears to be largely focused on obefazimod in ulcerative colitis (UC). However, Crohn's disease could represent a major additional growth driver, likely to significantly expand the addressable market and increase the strategic appeal of the programme. With this in mind, the read-out of the ENHANCE-CD study, expected in H2 2026, will be one of the most important catalysts on the project. We maintain our Outperform recommendation.
- Martial Descoutures
Abivax : Pourquoi la maladie de Crohn est-elle un enjeu majeur pour Ab...
À ce stade, l’intérêt spéculatif autour d’Abivax semble encore largement être orienté par obefazimod dans la rectocolite ulcéreuse (RCH). Cependant, la maladie de Crohn pourrait constituer un levier de croissance supplémentaire majeur, susceptible d’élargir significativement le marché adressable et d’augmenter l’attractivité stratégique du programme. Dans cette perspective, le read-out de l’étude ENHANCE-CD, attendu au S2 26, représente l’un des catalyseurs les plus importants sur le titre. Nous...
Abivax Publishes Financial Reports with the French and U.S. Securities...
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – April 1, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chr...
Disclosure of the total number of voting rights and shares composing t...
Disclosure of the total number of voting rights and shares composing the share capital as at March 31, 2026 Disclosure of the total number of voting rights and shares composing the share capital as at March 31, 2026 Articles L. 233-8-II of the French Commercial Code and 223-16 of the General Regulation of the Autorité des Marchés Financiers Saint-Rémy-lès-Chevreuse, April 1, 2026 DateTotal number of sharesTheoretical total number of voting rights1Net total number of voting rights2March 31, 202637,117,77237,117,77237,064,515 Investor Relations Contact / 64 ...
Information relative au nombre total de droits de vote et d'actions co...
Information relative au nombre total de droits de vote et d'actions composant le capital social au 31 mars 2026 Information relative au nombre total de droits de vote et d’actions composant le capital social au 31 mars 2026 Articles L. 233-8-II du Code de commerce et 223-16 du Règlement général de l’Autorité des marchés financiers Saint-Rémy-lès-Chevreuse, le 1er avril 2026 DateNombre total d’actions composant le capitalNombre total de droits de vote théoriques1Nombre total de droits de vote nets231 mars 202637 117 77237 117 77237 064 515 Contact Relations Investisseurs : / 64 ...
- Jean-François Granjon
- Louis Boujard
- CFA
EVT EVOTEC SE
PHA PHARMAGEST INTERACTIVE SA
ALDEL DELFINGEN INDUSTRY SA
OERL OC OERLIKON CORPORATION AG
VRAP VRANKEN-POMMERY MONOPOLE SA
NOEJ NORMA GROUP SE
POS PORR AG
ADN1 ADESSO AG
ALBFR SIDETRADE SA
SMHN SUESS MICROTEC AG
CSM CORBION NV
WPL WIRTUALNA POLSKA HOLDING SA
DMP DERMAPHARM HOLDING SE
ATRY ATRYS HEALTH
S30 SOLUTIONS 30 SE
KTA KNAUS TABBERT
LHYFE LHYFE S.A.
CO CASINO GUICHARD-PERRACHON
- Jean-François Granjon
- Louis Boujard
- CFA
EVT EVOTEC SE
PHA PHARMAGEST INTERACTIVE SA
ALDEL DELFINGEN INDUSTRY SA
OERL OC OERLIKON CORPORATION AG
VRAP VRANKEN-POMMERY MONOPOLE SA
VETO VETOQUINOL SA
NOEJ NORMA GROUP SE
POS PORR AG
ADN1 ADESSO AG
ALBFR SIDETRADE SA
SMHN SUESS MICROTEC AG
CSM CORBION NV
WPL WIRTUALNA POLSKA HOLDING SA
DMP DERMAPHARM HOLDING SE
ATRY ATRYS HEALTH
S30 SOLUTIONS 30 SE
KTA KNAUS TABBERT
LHYFE LHYFE S.A.
CO CASINO GUICHARD-PERRACHON
- Jeremy Garnier
- Jeremy Garnier
ID Logistics: 1 director
A director at ID Logistics bought 1,500 shares at 309.709EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
- Elias New
- Nicolas David
- Sinan Doganli
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.